Gilead Sciences Inc. (GILD) Dips 3.12% for February 16

Equities Staff  |

Among the S&P 500’s biggest fallers on Tuesday February 16 was Gilead Sciences Inc. (GILD). The stock experienced a 3.12% decline to $64.80 with 9.7 million shares changing hands.

Gilead Sciences Inc. started at an opening price of 66.41 and hit a high of $66.60 and a low of $64.52. Ultimately, the stock took a hit and finished the day at $2.09 per share. Gilead Sciences Inc. trades an average of n/a shares a day out of a total 1.25 billion shares outstanding. The current moving averages are a 50-day SMA of $n/a and a 200-day SMA of $n/a. Gilead Sciences Inc. hit a high of $85.98 and a low of $56.57 over the last year.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

With its headquarters located in Foster City, CA, Gilead Sciences Inc. employs 11,800 people. After today’s trading, the company’s market cap has fallen to $81.23 billion, a P/S of n/a, a P/B of 4.46, and a P/FCF of n/a.

Still paying commissions on stock trades? now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by

For all the attention paid to the Dow Jones Industrial Average (DJIA), it’s the S&P 500 that’s relied on by insiders and institutional investors. It represents the industry standard for American large-cap indices.

The Dow is made up of just 30 stocks to the S&P 500’s 500, and it uses an unreliable and outdated price-weighting system where the S&P 500 relies on market cap in weighting its returns. This is why its long-term returns is a much more reliable gauge for the performance of large- and mega-cap stocks over time.

To get more information on Gilead Sciences Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: GILD’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Market Movers